Public Companies
“Rags-To-Riches” Portfolio Outperformed The S&P 500 Last Week
The Rags-to-Riches Portfolio tracks the performance of a basket of 14 cannabis, psychedelic and plant-based food stocks with market capitalizations of…
The Rags-to-Riches Portfolio tracks the performance of a basket of 14 cannabis, psychedelic and plant-based food stocks with market capitalizations of at least $400M, and trading for at least $1/share.
An original article by Lorimer Wilson, Managing Editor of munKNEE.com – Your KEY To Making Money!
Below, by category, are how the various portfolio constituents are performing year-to-date and performed last week.
- American Cannabis MSO constituents:
- Cresco (CRLBF): + 7.4% YTD, +5.6% last week;
- Curaleaf (CURLF): -1.3% YTD, +2.7% last week;
- Green Thumb (GTBIF): +1.3% YTD, +13.9% last week;
- TerrAscend (TRSSF): +35.5% YTD, +19.2% last week;
- Trulieve (TCNNF): -12.3% YTD, +2.3% last week; and
- Verano (VRNOF): +2.9% YTD, +11.2% last week;
- In total: -1.0% YTD; Last week: +8.3%
- Read: 12 Largest American Cannabis MSO Stocks Up 7% Last Week
- Canadian Cannabis LP constituents:
- Canopy Growth (CGC): +28.6% YTD, -0.3% last week;
- Cronos (CRON): -1.1% YTD, No Change last week; and
- Tilray (TLRY): +19.9% YTD; -0.3% last week.
- In total: +15.4% YTD; Last week: -0.2%
- Read: 5 Largest Canadian Cannabis Stocks Flat Last Week
- Psychedelic Drug Stock constituents:
- Atai (ATAI): -27.5% YTD, +4.5% last week;
- Compass Pathways (CMPS): +31.6% YTD, -3.9% last week and
- GH Research (GHRS): -4.2% YTD; -5.4% last week
- In total: +6.7% YTD; Last week: -3.9%
- Read: 6 Largest Psychedelic Stocks Down 3% Last Week
- Plant-Based Food Stock constituents:
Total Portfolio Performance: +15.2% YTD; Last week +3.0%
The portfolio is outperforming the S&P 500 which was only +1.6% last week and is only +7.7% YTD. It compares unfavorably with the “Multi-bagger” Portfolio, however, which was +2.9% last week and is now +27.2% YTD.
psychedelic terrascend compass atai research-
Psychedelics1 week ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Law & Regulation1 week ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Psychedelics6 days ago
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
-
Psychedelics6 days ago
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
-
Psychedelics1 week ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics1 week ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Ketamine1 week ago
DEA poised to move cannabis to Schedule III
-
Psychedelics6 days ago
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment